SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
Patent Owner
Stats
- 102 US PATENTS IN FORCE
- 0 US APPLICATIONS PENDING
- Jan 07, 2016 most recent publication
Details
- 102 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 2,503 Total Citation Count
- Jun 28, 1974 Earliest Filing
- 350 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
| Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
- No Recent Publications to Display
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
9206133 Process for the synthesis of 7-chloro-4-(piperazin-1-yl)-quinolineJun 05, 12Dec 08, 15[C07D]
9114120 Therapeutical method for the treatment of the Leber optic neuropathySep 09, 11Aug 25, 15[A61K, A23L]
9023861 Anticancer combination of artemisinin-based drugs and other chemotherapeutic agentsDec 06, 10May 05, 15[A61K]
8883446 Human long pentraxin 3 expression system and uses thereofJul 20, 10Nov 11, 14[C12P, C12N, C07K]
8853233 Broad-spectrum anti-cancer treatment based on iminocamptothecin derivativesFeb 07, 08Oct 07, 14[A61K]
8822692 Diterpenoid derivatives endowed of biological propertiesJul 26, 13Sep 02, 14[A61K, C07D, C07C]
8778389 Medicament for the treatment of fungal infections particularly aspergillosisApr 28, 05Jul 15, 14[A61K]
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2016/0002,244 OXIDATED DERIVATIVES OF TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTSAbandonedAug 10, 15Jan 07, 16[A61K, C07D]
2015/0252,120 MODIFIED HYALURONIC ACID DERIVATIVES AND USE THEREOFAbandonedOct 07, 13Sep 10, 15[A61K, A23L, C08B, A61Q]
2014/0294,921 COMPOSITION FOR TIPICAL USE FOR TREATING SKIN DISORDERSAbandonedNov 28, 11Oct 02, 14[A61K]
2014/0079,809 COMPOUNDS USEFUL FOR THE PREVENTION OR TREATMENT OF ACCOMMODATIVE ASTHENOPIAAbandonedNov 18, 13Mar 20, 14[A61K]
8664210 Aminooxime derivatives of 2- and/or 4-substituted androstanes and androstenes as medicaments for cardiovascular disordersExpiredSep 18, 08Mar 04, 14[A61K, C07J]
2013/0236,551 COMBINATION COMPOSITION USEFUL FOR TREATING CARDIOVASCULAR DISEASESAbandonedNov 30, 10Sep 12, 13[A61K]
8530517 Retinoid derivatives endowed with cytotoxic and/or antiangiogenic propertiesExpiredDec 21, 09Sep 10, 13[A61K, C07C]
8518455 Dietary supplement enhancing the muscular energy metabolism, comprising an alkanoyl carnitine and riboseExpiredApr 02, 10Aug 27, 13[A61K]
2013/0203,848 COMPOUNDS USEFUL FOR INCREASING NEUROGENESIS IN NEURAL TISSUEAbandonedJun 10, 11Aug 08, 13[A61K]
2013/0122,033 FIMH VACCINE AGAINST URINARY TRACT INFECTIONS (UTI)AbandonedJun 28, 11May 16, 13[A61K]
8383616 Aryl isoxazole compounds with antitumoural activitiesExpiredJun 30, 09Feb 26, 13[A61K, C07D]
2013/0045,940 COMPOSITION COMPRISING AS ACTIVE INGREDIENT L-CARNITINE IN COMBINATION WITH A SOLAR FILTER, FOR THE PREVENTION AND/OR TREATMENT OF PATHOLOGIES OF THE EYE DUE TO ULTRAVIOLET RADIATIONAbandonedFeb 10, 11Feb 21, 13[A61K, A61P]
8377988 Use of L-carnitine or of alkanoyl L-carnitines for the preparation of a physiological supplement or medicament for ophthalmic use in the form of eye dropsExpiredDec 18, 09Feb 19, 13[A61K]
2013/0005,670 COMBINATION COMPOSITION, COMPRISING AS ACTIVE INGREDIENTS L-CARNITlNE OR PROPIONYL L-CARNITlNE, FOR THE PREVENTION OR TREATMENT OF CHRONIC VENOUS INSUFFICIENCYAbandonedFeb 07, 11Jan 03, 13[A61K, A61P]
2012/0258,993 NON-NATURAL MACROCYCLIC AMIDE HDAC6 INHIBITOR COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTSAbandonedSep 21, 10Oct 11, 12[A61K, C07D, A61P]
2012/0252,865 CARBAMATE DERIVATIVES IN PARTICULAR FOR THE TREATMENT OF NEUROLOGICAL DISORDERSAbandonedMar 08, 10Oct 04, 12[A61K, C07D, A61P]
Top Inventors for This Owner
| Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.
